Fig. 10: Tumors established from Ba/F3 cell lines with wild-type or indicated mutant EGFR showed different growth behavior in vivo.

a Tumor growth measurements by calipers: immunodeficient (NSG) mice were used to establish tumors in their flanks and tumor establishment and cumulative growth was monitored using calipers. N = 6 biologically independent animals per cohort, mean values plotted with error bars representing standard deviation (SD). b IVIS imaging of all animals from (a) at the experimental endpoint (day 41) showing epi-fluorescence signals from animal tumors. Radial efficiency was calculated as 10¹⁰(p/s/cm²/sr)/(μW/cm²). c GFP fluorescence signal quantification of tumors corresponding to N = 6 biologically independent animals in b. Statistical analysis by 1-way ANOVA (α = 0.05 and Tukey’s multiple comparison correction). * = 0.012; ** = 0.0029; *** = 0.0001-0.0006 (Supplementary Table 5). Data are presented as mean values; error bars are SD. d Harvested tumors from animals with established tumors were photographed under daylight. No tumors had established in the cohort that had received Ba/F3 + WT cells. e Tumor weights from harvested tumors of N = 6 biologically independent animals. Statistical analysis by 1-way ANOVA with Tukey’s multiple comparison correction: * = 0.0416; ** = 0.0013; **** <0.0001 (Supplementary Table 5; data are presented as mean values; error bars are SD). f Hematoxylin and eosin staining of tumors; scale bars are 100 μm. g Immunohistochemistry staining using a pan anti-EGFR antibody; corresponding background control staining is shown in Supplementary Fig. 10f. Scale bars are 100 μm. Source data are provided as a ‘Source data’ file.